September 29, 2019Open Access

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

Key points are not available for this paper at this time.

ClinicalTrials.gov identifier: NCT02107703.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Sledge et al. (Sun,) studied this question.

George W. Sledge

Masakazu Toi

Patrick Neven

JAMA Oncology

Stanford University

Inserm

Kyoto University

Building similarity graph...

Analyzing shared references across papers